drugset
drugset / Trial / NCT01471548

Phase I Dose Escalating Study of TKI258

NCT01471548 ↗

Phase 1 Completed 31 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of in this study is to assess the safety profile and estimate the maximum tolerated dose of TKI258 in Japanese patients.

Timeline

Start
2008-09
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule — Oral

Indications

cancer